Antonio D'Alessio
@A_DAlessioMD
Medical Oncologist and PhD student at Imperial College London. HCC, immuno-oncology. Curiosity-driven.
Just out on the @TheLancetOncol : our NeoHCC Study 🗞️ 📈 Path response after neoadj ICI predicts for RFS in HCC 🔥 HR 0.26 for RFS improvement with MPR 📊 30% of MPR is not predicted by ORR using RECIST 1.1 🎯 90% regression is the best threshold for RFS @DJPinato @ILCAnews
Presenting at #ILCA24 & published Online First: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with #hepatocellularcarcinoma: a cross-trial, patient-level analysis #livercancer @A_DAlessioMD @DJPinato thelancet.com/journals/lanon…
Thank you @ACortelliniMD for the kind words and for chairing such an inspiring session - and thank you @DJPinato for organising it and making it possible !
@A_DAlessioMD delivered a visionary talk at #ECIO25 on neoadjuvant immunotherapy strategies to 'cure' cancer. A bold and forward-thinking approach that's reshaping the future of oncology. 👏🧬 #ImmunoOncology #NeoadjuvantTherapy @ECIOcongress @cirsesociety @ImperialSandC
Ready for an exciting liver cancer day today at @ASCO #GI25 ! Come to say hi at my poster E9 📃 and discover how pathological response to neoadj IO in HCC predicts RFS better than RECIST 🩻 @ConquerCancerFd @DJPinato @ImperialSandC
Wonderful news - @ConquerCancerFd has chosen our work on neoadj ICI in HCC for the 2025 ASCO GI Merit Award🏅Pathological or radiological response as best RFS predictor? See you at my poster next Friday in San Francisco ! @DJPinato @ImperialSandC @ASCO conquer.org/news/conquer-c…
🙏Thank you very much for the great collaboration: @ArndtVogel @SaborowskiAnna @DJPinato @A_DAlessioMD @LorenzaRimassa @JDekervel @MarkusPeck1 @JohannvonFelden @balcar_lorenz @FulgenziClaudia and many more Editorial by: @MarcoSanduzzi @cabibbo78
🚨 Out now in @LiverInt: New scenarios in LT for HCC 👥 Led by a great international team in the field. @Alexfornergon @goncrespo1 @A_DAlessioMD @DJPinato @ColmeneroJordi @liverunitclinic @hospitalclinic @idibaps @BCLC_group @CHBPaulBrousse @HUReinaSofia onlinelibrary.wiley.com/doi/10.1111/li…
#spatial #singlecell analysis revealed #immune architecture related to response to #immunotherapy in #hcc. Nice work & #congratulations @A_DAlessioMD @DJPinato @Therealbbengsch
Read from the paper @HenrikeSalie et al "Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma" via bit.ly/4eRMjx4 @teximmed2 @Uniklinik_Fr…
Thank you @DJPinato for leading this work, as enthusiastically as ever !
Have you finally found a predictive biomarker, in #HCC 🔥 @A_DAlessioMD ? 🔬 @ILCAnews @ImperialSandC #ILCA24 @myESMO @ASCO thelancet.com/journals/lanon…
Thank you @Valeriechew29 ! Lots of translational work ahead 🔬
Congratulations! @A_DAlessioMD @DJPinato for your study with #neohcc consortium. Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis - The Lancet Oncology thelancet.com/journals/lanon…
Looking forward to seeing many friends and colleagues in Hong Kong !! @ILCAnews
What’s next for systemic therapy in liver cancer? At #ILCA25, @StephenLChan1, @riadsalemIR, @LorenzaRimassa & @A_DAlessioMD will explore the future of #HCC & #CCA treatment in the session “Advances in Systemic Therapy & Encore Presents”. 📍Hong Kong: shorturl.at/56RDG
Great talk and discussion by @graokane on #immunotherapy before #livertransplant for #HCC at #EASL2025 @SherrieBhoori @A_DAlessioMD @EASLnews @EASLedu
This afternoon at #EASLCongress, experts are taking on the complexities of hepatocellular carcinoma management in a fast-evolving therapeutic landscape. Discussion is centred around how to select patients for immune checkpoint inhibitors before liver transplantation, when…
The calm before the storm... 🎙️ What a pleasure to share the stage with a stellar panel to talk about the challenges of ICI in HCC patients with impaired liver function at #easl25 @EASLedu @EASLnews
Thank you @EASLedu for the great session - today we learnt a lot about combined HCC-CCA 🎯 1. The diagnostic challenges - from the POV of pathology and radiology 2. How to integrate surgery and SIRT 3. Molecular profiling for targeted treatment @NaultJc @valerie_paradis #easl2025
🤔 @A_DAlessioMD reflects on "how could we have done better?" in the management of this clinical case: 1. Treatment sequence: targeted therapy vs chemo-ICI 2. Integration of locoregional treatments? How to best exclude extrahepatic disease? 3. Consider a re-biopsy…
Are you at #easl2025 ? Don't miss this interactive session today ! See you at the Track Hub 3 - Liver Tumours at 13h30 @EASLedu
🔴 EASL Molecular Tumour Board is starting in 1 hour! 👉🏽 Join us at the Track Hub 3 - Liver Tumours in Hall 12 at 13:30 CEST @EASLnews @A_DAlessioMD @NaultJc @valerie_paradis @SaborowskiAnna @Yujun__Wong @FrancqueSven #EASLMTB
Join us tomorrow onsite at #EASLCongress 2025! 🧪 EASL Molecular Tumour Board 📅 Wednesday 7 May, 13:30 - 14:30 CEST 📍 Hall 12 - Track Hub 3: Liver tumours 🔗 events-apps.easl.eu/easl2025/en-GB… Take part in this educational session to learn more about the challenges in diagnosis and…
We'll done @angelopirozzi3 ! Super well deserved - can't wait to see your follow-up work !
Do you remember adjuvant cell therapy for HCC? 🧫 At @ASCO #GI25 the NINE year (!) f-up was presented: 📈 maintained significant RFS benefit 📍 reduction in cancer-specific death 🧪increase in CD8+ memory T cells Adjuvant therapy for HCC: not everything is lost ?
RACB Study: interesting trial design of conversion therapy with AtezoBev in initially unresectable HCC 🩺 However: ❓ PR 13%, but resection rate 48% 🧐 Any grade AEs 66% ❌ No standardised definition of unresectable HCC @ASCO #GI25
CARES-005 is positive ! Another IO-TACE positive trial...but doubts remain 🧐 ❓PFS with TACE: 3.2 months only ❌ OS negative 🥈 phase 2 @ASCO #GI25
